Serelaxin in acute heart failure: Most recent update on clinical and preclinical evidence

Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF

(2016) Licette C. Y. Liu et al.   Clinical Research in Cardiology

Increased alcohol consumption in relaxin-3 deficient male mice

(2016) Takahira Shirahase et al.   NEUROSCIENCE LETTERS

Use of High-Sensitivity Troponin T to Identify Patients With Acute Heart Failure at Lower Risk for Adverse Outcomes

(2016) Peter S. Pang et al.   JACC-Heart Failure

Pharmacokinetics of serelaxin in patients with hepatic impairment: a single-dose, open-label, parallel group study

(2015) Zhanna Kobalava et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Heart Disease and Stroke Statistics—2016 Update

(2015) Dariush Mozaffarian et al.   CIRCULATION

Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Serelaxin in Japanese Patients With Acute Heart Failure

(2015) Naoki Sato et al.   CIRCULATION JOURNAL

Serelaxin and acute heart failure

(2015) Jeremy Tietjens et al.   HEART

Safety and tolerability of serelaxin, a recombinant human relaxin-2 in development for the treatment of acute heart failure, in healthy Japanese volunteers and a comparison of pharmacokinetics and pharmacodynamics in healthy Japanese and Caucasian populat

(2015) Marion Dahlke et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Rationale and design of PRIMA II: A multicenter, randomized clinical trial to study the impact of in-hospital guidance for acute decompensated heart failure treatment by a predefined NT-PRoBNP target on the reduction of readmIssion and Mortality rAtes

(2014) Susan Stienen et al.   AMERICAN HEART JOURNAL

Vascular oxidative stress, nitric oxide and atherosclerosis

(2014) Huige Li et al.   ATHEROSCLEROSIS

Renal Hemodynamic Effects of Serelaxin in Patients With Chronic Heart Failure

(2014) Adriaan A. Voors et al.   Circulation-Heart Failure

Effect of Serelaxin on Mode of Death in Acute Heart Failure

(2014) G. Michael Felker et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Relaxin Suppresses Atrial Fibrillation by Reversing Fibrosis and Myocyte Hypertrophy and Increasing Conduction Velocity and Sodium Current in Spontaneously Hypertensive Rat Hearts

(2013) Ashish Parikh et al.   CIRCULATION RESEARCH

Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial

(2013) G. Filippatos et al.   EUROPEAN HEART JOURNAL

A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure

(2013) Piotr Ponikowski et al.   EUROPEAN HEART JOURNAL

Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF

(2013) M. Metra et al.   EUROPEAN HEART JOURNAL

The annual global economic burden of heart failure

(2013) Christopher Cook et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Pathophysiology-based novel pharmacotherapy for heart failure with preserved ejection fraction

(2013) Dimitrios M. Konstantinou et al.   PHARMACOLOGY & THERAPEUTICS

Relaxin Family Peptides and Their Receptors

(2013) R. A. D. Bathgate et al.   PHYSIOLOGICAL REVIEWS

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC

(2012) et al.   EUROPEAN HEART JOURNAL

Effect of Serelaxin on Cardiac, Renal, and Hepatic Biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) Development Program

(2012) Marco Metra et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial

(2012) John R Teerlink et al.   LANCET

Relaxin Signals through a RXFP1-pERK-nNOS-NO-cGMP-Dependent Pathway to Up-Regulate Matrix Metalloproteinases: The Additional Involvement of iNOS

(2012) Bryna Suet Man Chow et al.   PLoS One

Maternal vasodilation in pregnancy: the emerging role of relaxin

(2011) Kirk P. Conrad   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

Angiogenic Growth Factors Are New and Essential Players in the Sustained Relaxin Vasodilatory Pathway in Rodents and Humans

(2011) Jonathan T. McGuane et al.   HYPERTENSION

Relaxin Ameliorates Hypertension and Increases Nitric Oxide Metabolite Excretion in Angiotensin II But Not N ω -Nitro- l -Arginine Methyl Ester Hypertensive Rats

(2011) Jennifer M. Sasser et al.   HYPERTENSION

Relaxin ameliorates salt-sensitive hypertension and renal fibrosis

(2011) T. Yoshida et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity scoring methods

(2010) Alexandre Mebazaa et al.   INTENSIVE CARE MEDICINE

Usefulness of Isosorbide Dinitrate and Hydralazine as Add-on Therapy in Patients Discharged for Advanced Decompensated Heart Failure

(2009) Wilfried Mullens et al.   AMERICAN JOURNAL OF CARDIOLOGY

Intravenous Recombinant Human Relaxin in Compensated Heart Failure: A Safety, Tolerability, and Pharmacodynamic Trial

(2009) Thomas Dschietzig et al.   JOURNAL OF CARDIAC FAILURE

Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study

(2009) John R Teerlink et al.   LANCET

Sodium Nitroprusside for Advanced Low-Output Heart Failure

(2008) Wilfried Mullens et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY